Comply FDA names new Editor-in-Chief

Comply FDA names new Editor-in-Chief
Industry leader Michael Kuehne takes the reigns.

Press Release ( - NORTH BRUNSWICK, N.J. - Nov 15, 2017 - Comply FDA has named Michael Kuehne as their new editor in chief. Mr. Kuehne is an industry leader with more than twenty years’ experience in the areas of quality and compliance for life science organizations.

Under Mr. Kuehne’ s supervision, Comply FDA has rolled out updated products that provide a clear comprehensive overview of how to meet inspection guidelines issued by the FDA.

Michael Kuehne is the Senior Vice President of Quality, Compliance & Regulatory Affairs at Cyalume Technologies. In addition Mr. Kuehne is also actively mentoring future professionals attending the Rutgers School of Engineering.

“We’ve taken the mystery out of managing FDA compliance by providing benchmarking information and best practice principles in the form of Intelligence insights and reports”. M.Kuehne.

Comply FDA products are integral to developing and implementing effective solutions for quality and compliance. The ability of organizations to develop and implement effective rbofa solutions for quality and compliance issues depends on their ability to correctly identify problems and proactively establish, implement and monitor robust solutions significantly reducing compliance risk while improving overall quality.

Mr Kuehne went on to say “Our product provides a clear comprehensive overview of how to meet inspection guidelines issued by the FDA.”

Please visit to view all products offered to the Pharmaceutical, Medical Device and Biologic “life science” industries.

Source : ComplyFDA

You may also like this  


Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or Signup using Email

Already have an account ? Login

Reset Password

Already have an account ? Login


If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/ services/ business mentioned and hereby disclaims any content contained in this press release.